ISPOR First Asia-Pacific Conference: Preliminary program

Tuesday, 2 September
8.00-9.00	EXHIBITS, AND RESEARCH PRESENTATION - POSTER VIEWING reception hall, 3rd floor
	Poster Presentations
9.00- 10.30	FIRST PLENARY SESSION international conference room 301, 3rd floor
9:00- 9:30	OPENING REMARKS
9:00-9:10	WELCOME Speaker: Isao Kamae MD, DrPH, Research Center for Urban Safety and Security, and Graduate School of Medicine, Kobe University, Kobe, Japan
9:10-9:20	CONFERENCE INTRODUCTIONS Speakers: Naoki Ikegami MD, MA, School of Medicine, Keio University, Tokyo, Japan and Shuzo Nishimura PhD, Faculty of Economics, Kyoto University, Kyoto, Japan
9:20-9:30	ISPOR PRESIDENT REMARKS Speaker: Sean Sullivan PhD, University of Washington, Seattle, Washington, USA
9.30-10:45	FIRST PLENARY SESSION international conference room 301, 3rd floor
9.30-9:35	Role of Pharmacoeconomics and Outcomes Research in Healthcare Decisions Moderators: Toshihiko Hasegawa MD, Director of Health Policy Science, National Institute of Public Health, Department of Policy Sciences, Saitama-ken, Japan and Koichi Nobutomo MD, DMSc, Professor of Healthcare Systems, Graduate School of Medicine, Kyushu University, Fukuoka, Japan
9.35-9:50	Importance of Healthcare Quality and Outcomes Research in Health Care Reform: A Policy-maker’s Perspective Speaker: Honorable David F. Durenberger, Chairman and CEO, National Institute for Health Policy; President, Medical Technology Leadership Forum; and US Senator (1978-1995), Minneapolis, MN, USA Senator Durenberger will identify the common challenges that all developed nations face in managing their health care systems and describe previous attempts at reform. His remarks will conclude with a discussion of current policy solutions and underscore the important role that Health Services Research must play in bringing about global health care reform.
9:50-10.10	The Role of Pharmacoeconomic Guidelines in Drug Selection Healthcare Decisions Speaker: Sean Sullivan PhD, Professor, University of Washington, Seattle, WA, USA Pharmacoeconomic evaluations play an increasingly important role in resource allocation decisions in a few select countries. In order to improve relevance and transparency, guidelines have been introduced in some countries that detail evidentiary requirements for decision-making, methodologic conduct for research and ethical responsibilities for analysts and sponsors. Do decision-makers use economic analyses? Is the evidence for economic impact sufficiently rigorous and unbiased? Dr. Sullivan will explore these issues and make recommendations for improving the conduct and use of pharmacoeconomics for resource allocation.
10.10-10:30	Health Care Reform in Japan Speaker: Ryoji Takahara MD, MPH, Director-General, Health Bureau, Ministry of Health, Labour and Welfare of Japan
10:30-10:45	Break
10:45-11:45	WORKSHOPS SESSION I (4 concurrent sessions)
	Clinical Studies room 403
W1	PRINCIPLES OF GOOD PRACTICE FOR EBM AND MODELING IN HEALTH CARE EVALUATION Kamae I¹, Inoue Y², Koizumi S³, ¹Kobe University, Kobe, Japan; ²Yamaguchi University, Yamaguchi, Japan; ³Saga Medical School Hospital, Saga, Japan Learning Objectives: Review the standard criteria for critical appraisal and problem-solving in evidence-based medicine (EBM), and also understand the guidelines for modeling studies reported by the ISPOR Task Force; gain a better appreciation of how outcomes researchers link clinical practice with modeling studies. Workshop Description: In recent years, need for EBM has been growing in clinical practice. EBM community already established the standard criteria for clinicians in critically appraising the quality of patient-oriented outcomes research. It is important for not only clinicians, but also any outcomes researchers to review what it is and what it means in teams of conducting good research with scientific soundness. The ISPOR Task Force on good research practices recently published the consensus of the discussion with guidelines for modeling studies. The guidelines, of course, are worth understanding for any health-care researches. The workshop gives an opportunity to understand the criteria in EBM for good clinical studies and appreciate a linkage between clinical practice and outcomes research in the light of focusing on good modeling. A case study will be presented with the cost-effectiveness analysis in the Interferon use for hepatitis.
	Pharmacoeconomics room 402
W2	METHODOLOGICAL ISSUES ON WILLINGNESS-TO-PAY-TAX Chi C¹, Lang HC², ¹Oregon State University, Corvallis, OR, USA; ²National Yang-Ming University, Taipei, Taiwan Learning Objectives: To review key literature on WTP and WTPT, differentiating between the two, knowing methods for measuring WTP general and earmarked tax and policy implications of WTPT methods. Workshop Description: Willingness-to-pay (WTP) is a standard method to solicit consumer preferences for non-market goods, especially in health care services. The finance of health care in most OECD nations, however, is primarily through either general tax or earmarked tax, which include premiums, collected by government. Willingness-to-pay-tax (WTPT), therefore, emerged as an important research and policy issue in resource allocation and public finance, which is different from conventional WTP method. The first part of this workshop reviews key literature on WTP and WTPT. This is followed by raising and discussing several critical methodological issues in measuring WTPT, and where it departs from WTP. Special attention is given to WTPT measurement methods in relation to general tax and earmarked tax. Because these two types of taxes present different challenges in measurement, their treatments are discussed separately. Further, as user charges or cost sharing are increasingly present in many health care systems, and its underlying methodological issues are resemblance to WTPT, these issues are also considered here. On the third part, this paper proposes method for measuring willingness to pay general tax and earmarked tax. On the fourth part, given that WTPT solicitation is inevitably leads to resource allocation decisions and priority settings, the author discusses the policy implications of WTPT methods. Further, various concerns in equity related to WTPT are also discussed. Finally, the author recommends areas of WTPT that calls for further investigation and development.
	Quality of Life room 401
W3	TRANSLATION AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES Crawford B¹, Conway K², Abetz L³, ¹Mapi Values, Boston, MA, USA; ²Mapi Research Institute, Lyon, France; ³Mapi Values, Cheshire, UK Learning Objectives: To become familiar with the validation process and quality of life questionnaires. Workshop Description: International clinical trials evaluating quality of life require questionnaires that are culturally adapted into the local language. In addition, whenever a questionnaire is translated into a new language or used in a new population, it is recommended that the validation of the questionnaire be completed by checking the following psychometric properties. This workshop will review the translation process with an emphasis on conceptual equivalence and review the validation process, including validity, reliability and responsiveness. Examples will be provided to enhance learning. Attendees will be trained to understand translation processes and standard validation techniques.
	Health Policy international conference room 301
W4	FORMULARY DEVELOPMENT USING PHARMACOECONOMICS Neumann P¹, Sullivan S², Foote S³, ¹Harvard School of Public Health, Boston, MA, USA; ²University of Washington, Seattle, WA, US; ³School of Public Health, University of Minnesots, Minneapolis, MN. USA Learning Objectives: To learn guidelines and review formulary development using pharmacoeconomics for the future. Workshop Description: Health plans, pharmacy benefits managers, state Medicaid programs and hospitals in the U.S. have long used drug formularies, which list the prescription medications approved for routine use in the organizations. But the process by which these organizations made formulary decisions has frequently lacked transparency or scientific rigor. In recent years, health policy makers have worked to standardize and improve formulary processes, with the goal of grounding decisions in stronger clinical and economic evidence. The trend reflects two broader movements in health care, one towards evidence-based medicine, and the other towards explicit consideration of cost-effectiveness or "value for money" arguments. The U.S. has trailed other countries in its adoption of formulary guidelines but a growing number of health plans and other organizations have begun to implement new formulary guidelines issued by the Academy of Managed Care Pharmacy (AMCP). This workshop will describe the guidelines, review progress to date, and analyze critical issues for the future. Specifically, we will the following questions: What information is requested in the AMCP Format? How will the Format change practices at health plans and pharmaceutical companies? Will the Format impose an undue burden on health plans and manufacturers? Do health plans have the expertise to use them? Are formulary guidelines a smokescreen for cost-containment? Do plans have the clout to force drug companies to comply? Won’t all drug company submitted information be "biased?" How will the FDA regulate unsolicited requests? Are dossiers submitted under the AMCP Format confidential?
11:45-12:00	Break
12:00-13:00	WORKSHOPS SESSION II (4 concurrent sessions)
	Clinical Studies room 403
W5	J-ARAMIS, A NEWLY ESTABLISHED LARGE OBSERVATIONAL COHORT OF JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS Yamanaka H¹, Singh G², Tanaka EI¹, Nakajima A¹, Kamatani N¹; ¹Tokyo Women's Medical University, Tokyo, Japan; ²Stanford University, Palo Alto, CA, USA Learning Objectives: To review and understand the foundations of the J-ARAMIS program and its relation to Japanese patients with rheumatoid arthritis. Workshop Description: Rheumatoid arthritis (RA) and osteoarthritis are the most common rheumatic diseases in Japan. Outcome studies in these chronic diseases require systematic protocol-driven collection of long-term data. Although there have been a few epidemiological studies in Japan, there is no system for systematically collecting long-term outcome data in patients with arthritis. In this workshop, we report the establishment of the first such system. Methods: The J-ARAMIS program is set up as a prospective non-interventional observational cohort study of consecutively enrolled patients with arthritis. Patients are asked to answer a validated questionnaire (J-HAQ) at clinic visit or complete it at home and mail it back. The questionnaire includes validated items on disability, pain, medication use, adverse events, health care utilization, and satisfaction with care. Finally, a combined database is made by inclusion of patient-reported data, physician's assessment, and laboratory data set. Discussion: The first phase of J-ARAMIS was done in October 2000. Patient questionnaires were administered to 4110 consecutively enrolled patients with rheumatic diseases. A total of 4047 patients answered the questionnaires, for a response rate of 98.5%. Of these, 3763 patients had RA. This cohort is designed to be followed twice per year and J-ARAMIS database is expected to accumulate more than 1000 characteristics of these patients for at least five years. Although the system has just established, J-ARAMIS is expected to produce useful data for the assessment of RA. These include the ethnic difference in pharmacogenomics, one of the major concerns of clinical rheumatology. The near-perfect response rate indicates that such studies are practical and possible in Japan, and are likely to yield a high quality of epidemiologic data on rheumatic diseases in Japan.
	Pharmacoeconomics room 402
W6	INSTITUTIONAL COST ANALYSIS EMPLOYING MICROSOFT EXCEL: AN EFFICIENT APPROACH FOR DEVELOPING COUNTRIES
	Riewpaiboon A, Mahidol University, Rajathevi, Bangkok, Thailand Learning Objective: This workshop is aimed to introduce and exchange experience on the efficiently institutional cost analysis employing Microsoft Excel. Workshop Description: Institutional cost analysis is important for public health planning and efficiency management. Cost data systems in developing countries are usually not well organized and not computerized. In this situation, a specific developed approach is needed to facilitate the analysis. The workshop will present conventional cost analysis methodology composing of bottom-up and top-down approaches, economic depreciation cost using inflation-adjusted current price, simultaneous equation method for indirect cost allocation, departmental allocation to unit cost by various techniques. To conduct the analysis efficiently, Microsoft Excel is employed creating an automatic-updated calculation instrument. The Excel techniques comprise cell referencing, linking, transposed linking, copying of linking, copying of formula, and Excel functions i.e. IF, LOOKUP, YEAR, MINVERSE and MMULT. This cost analysis instrument acts similar to a software convenient to do sensitivity analysis and update analysis in following years.
	Quality of Life room 401
W7	RECENT DEVELOPMENT ON THE MEASUREMENT OF GENERIC QOL IN JAPAN Nishimura S¹, Ikeda S², Ohkusa Y³, ¹Kyoto University, Kyoto, Japan: ²Keio University, Tokyo, Japan; ³Osaka University, Osaka, Japan
	Health Policy International Conference Room 301
W8	PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES IN CHINA Hu S, School of Public Health, Fu Dan University, Shanghai, P.R China Learning Objectives: To evaluate the present pricing and reimbursement policies of pharmaceuticals in China and to discuss how to improve the policy-making on setting rational drug prices and reimbursement lists. Workshop Description: In China, the share of pharmaceutical expenditures accounted for 47~56% in national health accounts during the past decade. The average annual growth rate of pharmaceutical expenditures was 11.2% higher than that of gross domestic product. During this workshop the changes of pricing policy, which has gradually shifted from fixed cost markup to social average pricing and bulk procurement through price bidding will be presented. As a result of changes in the pricing policy, some negative impacts have occurred in the process of pooled purchasing. Although multiple approaches have been adopted, a significant savings in pharmaceutical expenditure has not occurred. Alternative drug policy reimbursement plans will be discussed such as reference-based pricing schemes and price negotiation with pharmaceutical companies as a future direction to healthcare cost containment. Workshop participants will be asked to share experiences with drug reimbursement policies in their country.
13:00-15:30	LUNCH, EXHIBITS, AND RESEARCH PRESENTATION - POSTER VIEWING reception hall, 3rd floor
	Poster Presentations
15:30-17.00	SPECIAL SESSIONS (2 concurrent sessions)
15:30-17.00	THE JAPANESE HEALTH CARE SYSTEM: STRUCTURE, DYNAMICS, LESSONS room 401 Speaker: Naoki Ikegami MD, MA, Professor and Chair, Department of Health Policy & Management, School of Medicine, Keio University, Tokyo, Japan Japan's health indices are excellent although health expenditures constitute only 7.6% of the GDP in 2000. The structure and the forces that drive the system will be explained. The lecture will conclude with projections about the future and lessons for other countries in the Asia-Pacific region.
15:30-17.00	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN ASIA-PACIFIC international conference room 301 Co-sponsored by: The Japan Society of Pharmacoepidemiology (JSPE), the International Society for Pharmacoepidemiology (ISPE), and ISPOR Organized by: Takashi Fukuda, PhD, Associate Professor, Department of Pharmacoeconomics, University of Tokyo, Tokyo, Japan; Shunya Ikeda, MD, MS, DMSc, Assistant Professor, Department of Policy and Management, Keio University, Keio, Japan; Makoto Kobayashi, ME, Manager, CRECON Research and Consulting Inc., Tokyo, Japan; Kiichiro Tsutani, MD, PhD (chair), Professor, Department of Pharmacoeconomics, University of Tokyo, Tokyo, Japan Moderator: Kiichiro Tsutani MD, PhD, Professor, Department of Pharmacoeconomics, University of Tokyo, Tokyo, Japan For the sound and efficient study of both pharmacoepidemiology and pharmacoeconomics, high quality datasources are necessary. Datasources in the Asia-Pacific region are in various stages of development and use. This Special Session aims: (1) to review the current status of datasources in Asia-Pacific in these two fields; (2) to identify problems encountered; and (3) to develop future plans for development.
15:40-15.55	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN AUSTRALIA Speaker: Peter Davey MA, Director, M-TAG, Chatswood , NSW, Australia
15:55–16:10	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN CHINA Speaker: S. Hu PhD, Professor, School of Public of Health, Fudan University, Shanghai, China
16:10–16:25	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN THE REPUBLIC OF KOREA Speakers: Byung Joo Park, MD, PhD, Professor, Seoul National University College of Medicine, Seoul, Korea; Sang-Cheol Bae, MD, PhD, MPH, Head of Rheumatology Division, Hanyang University, Seoul, Korea
16:25–16:45	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN JAPAN Speakers: Takuro Shimbo, MD, DMs, Associate Professor, General Medicine and Clinical Epidemiology Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kiichiro Tsutani, MD, Professor, Department of Pharmacoeconomics, University of Tokyo, Tokyo, Japan; Takashi Fukuda, PhD, Associate Professor, Department of Pharmacoeconomics, University of Tokyo, Tokyo, Japan; Shunya Ikeda MD, MS, DMSc, Assistant Professor, Department of Policy and Management, Keio University, Keio, Japan; Makoto Kobayashi, ME, Manager, CRECON Research and Consulting Inc., Tokyo, Japan; Masashi Kusunoki
16:45–17:00	DATASOURCES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS STUDIES IN TAIWAN Speaker: Yen-Huei (Tony) Tarn PhD, Associate Professor, School of Pharmacy, National Defense Medical Center, Taipai, Taiwan
17.00-18.00	RECEPTION, EXHIBITS, AND RESEARCH PRESENTATIONS - POSTER VIEWING
	Poster Presentations
17.00-18.00	SATELLITE SYMPOSIUM International Conference Room 301
	KOBE MEDICAL DEVELOPMENT PROJECT IN THE 21ST CENTURY Moderator: Masayoski Murakami MD, Director of Clinical Research Coordination, Foundation of Biomedical Research and Innovation, Kobe, Japan THE NEED FOR TECHNOLOGY ASSESSMENT IN HEALTH CARE Speaker: Peter Neumann ScD, Associate Professor of Policy & Decision Science, Harvard School of Public Health, Boston, MA, USA BUSINESS DEVELOPMENT & TECHNOLOGY ASSESSMENT Speaker: J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA
18.30-21.00	BAY-CRUISING ON THE “CONCERTO” (Optional) – includes dinner and drinks (see ISPOR registration desk to purchase tickets – US$36 or ¥ 4500)

BAY-CRUISING ON THE “CONCERTO” (Optional) – includes dinner and drinks (see ISPOR registration desk to purchase tickets – US$36 or ¥ 4500)